Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01986569
What this trial is testing

Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer

Who this might be right for
Recurrent Breast CancerStage IV Breast Cancer
Asan Medical Center 93
Testing effectiveness (Phase 2)Study completedNCT00234403
What this trial is testing

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 60
Not applicableNot Yet RecruitingNCT07597642
What this trial is testing

ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
IRCCS San Raffaele 55
Not applicableAvailableNCT07643831
What this trial is testing

Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

Who this might be right for
ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
Genentech, Inc.
Testing effectiveness (Phase 2)UnknownNCT01709370
What this trial is testing

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

Who this might be right for
ER Positive, HER2 Negative Breast Cancer
Organisation for Oncology and Translational Research 45
Early research (Phase 1)Study completedNCT04097756
What this trial is testing

A Phase I Study of LX-039 Tablets

Who this might be right for
Advanced Breast Cancer
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. 44
Not applicableActive Not RecruitingNCT07541703
What this trial is testing

Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer

Who this might be right for
Breast CancerEarly Breast CancerER-Positive HER2-Negative Breast Cancer
Spotlight Medical 2,200
Large-scale testing (Phase 3)UnknownNCT00532727
What this trial is testing

Triple Negative Breast Cancer Trial

Who this might be right for
Breast Cancer
Institute of Cancer Research, United Kingdom 400
Testing effectiveness (Phase 2)Study completedNCT02988986
What this trial is testing

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

Who this might be right for
Estrogen Receptor Positive Breast Cancer
The Methodist Hospital Research Institute 28
Testing effectiveness (Phase 2)Ended earlyNCT02681523
What this trial is testing

ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.

Who this might be right for
Breast Cancer
Imperial College London 8
Large-scale testing (Phase 3)Looking for participantsNCT07541079
What this trial is testing

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Who this might be right for
Early Breast Cancer
Genentech, Inc. 300
Testing effectiveness (Phase 2)Study completedNCT03620643
What this trial is testing

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Who this might be right for
Lobular Breast CarcinomaGastric CancerTriple Negative Breast Cancer+1 more
Royal Marsden NHS Foundation Trust 33
Large-scale testing (Phase 3)Active Not RecruitingNCT04711252
What this trial is testing

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 1,370
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 880
Not applicableStudy completedNCT01926964
What this trial is testing

Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer

Who this might be right for
Breast Cancer
Swiss Cancer Institute 229
Testing effectiveness (Phase 2)Study completedNCT01783444
What this trial is testing

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 309
Testing effectiveness (Phase 2)Study completedNCT01421472
What this trial is testing

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Who this might be right for
ER Positive, Her2 Negative Breast Cancer PatientsTriple Negative Breast Cancer Patients
Merrimack Pharmaceuticals 196
Not applicableStudy completedNCT01081600
What this trial is testing

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition

Who this might be right for
Breast Cancer
University Medical Center Groningen 7
Testing effectiveness (Phase 2)Study completedNCT00559507
What this trial is testing

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Who this might be right for
Estrogen Receptor-negative Breast CancerMale Breast CancerProgesterone Receptor-negative Breast Cancer+4 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Ended earlyNCT05932667
What this trial is testing

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Institut Curie 1
Next Page